Middle East and Africa transfection reagents and equipment market is projected to register a substantial CAGR of 7.0% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030. Market Segmentation: Middle East and Africa Transfection Reagents and Equipment Market, By Products (Reagent & Kits and Instruments), Stage (Research, Preclinical, Clinical Phases, and Commercial), Type (Transient Transfection Reagents and Equipment, Stable Transfection Reagents, and Equipment), Methods (Non-viral Methods and Viral Methods), Types of Molecule (Plasmid DNA, Small Interfering RNA (siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes (RNPs), and Others), Organism (Mammalian Cells, Plants, Fungi, Virus, and Bacteria), Application (By Type and By Industry), End User (Biopharma, Contract Research Organizations (CROs), Contract Manufacturing Organization/ Contract Development and Manufacturing Organization (CMOs/CDMOs), Academia, Hospitals, Clinical Labs, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Saudi Arabia, South Africa, U.A.E, Israel, Egypt, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030 Some of the drivers that boost transfection reagents and equipment market’s growth are as follows: • Strategic initiatives by market players • Large-scale transfections used in clinical research Market Players: Some of the major players operating in the Middle East and Africa transfection reagents and equipment market are: • Mirus Bio LLC. • Promega Corporation • Cytiva • OriGene Technologies, Inc. • Beckman Coulter, Inc. (A Subsidiary of Danaher)

1 INTRODUCTION 18 1.1 OBJECTIVES OF THE STUDY 18 1.2 MARKET DEFINITION 18 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET 18 1.4 LIMITATIONS 22 1.5 MARKETS COVERED 22 2 MARKET SEGMENTATION 28 2.1 MARKETS COVERED 28 2.2 GEOGRAPHICAL SCOPE 29 2.3 YEARS CONSIDERED FOR THE STUDY 30 2.4 CURRENCY AND PRICING 30 2.5 DBMR TRIPOD DATA VALIDATION MODEL 31 2.6 MULTIVARIATE MODELLING 34 2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE 34 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35 2.9 DBMR MARKET POSITION GRID 36 2.10 MARKET APPLICATION COVERAGE GRID 37 2.11 VENDOR SHARE ANALYSIS 38 2.12 SECONDARY SOURCES 39 2.13 ASSUMPTIONS 39 3 EXECUTIVE SUMMARY 40 4 PREMIUM INSIGHT 43 4.1 PESTEL 44 4.2 PORTER'S FIVE FORCES MODEL 45 5 INDUSTRY INSIGHTS: 46 6 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, REGULATIONS 47 6.1 EUROPEAN UNION REGULATORY SCENARIO 47 6.2 U.S. REGULATORY SCENARIO 48 6.3 JAPAN REGULATORY SCENARIO 48 6.4 CHINA REGULATORY SCENARIO 49 7 MARKET OVERVIEW 51 7.1 DRIVERS 53 7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES 53 7.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS 54 7.1.3 GROWING DEMAND FOR CHIMERIC GENES 54 7.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH 55 7.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS 55 7.2 RESTRAINTS 56 7.2.1 HIGH COST OF TRANSFECTION PRODUCTS 56 7.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS 56 7.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE 57 7.3 OPPORTUNITIES 57 7.3.1 EXPLORATION OF EMERGING MARKET 57 7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 58 7.3.3 SURGING LEVEL OF INVESTMENT 59 7.4 CHALLENGES 59 7.4.1 LONG APPROVAL PROCEDURE 59 7.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS-ASSOCIATED TRANSFECTION 60 7.4.3 LACK OF TRAINED PROFESSIONALS 61 8 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS 62 8.1 OVERVIEW 63 8.2 REAGENTS & KITS 66 8.3 INSTRUMENTS 67 9 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE 69 9.1 OVERVIEW 70 9.2 RESEARCH 73 9.3 PRECLINICAL 73 9.4 CLINICAL PHASES 74 9.5 COMMERCIAL 75 10 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE 77 10.1 OVERVIEW 78 10.2 TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT 81 10.3 STABLE TRANSECTION REAGENTS AND EQUIPMENT 81 11 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY METHODS 83 11.1 OVERVIEW 84 11.2 NON-VIRAL METHODS 87 11.3 VIRAL METHODS 87 12 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE 89 12.1 OVERVIEW 90 12.2 PLASMID DNA 92 12.3 SMALL INTERFERING RNA (SIRNA) 93 12.4 PROTEINS 94 12.5 DNA OLIGONUCLEOTIDES 95 12.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS) 96 12.7 OTHERS 96 13 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM 98 13.1 OVERVIEW 99 13.2 MAMMALIAN CELLS 101 13.3 PLANTS 102 13.4 FUNGI 103 13.5 VIRUS 104 13.6 BACTERIA 105 14 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY APPLICATION 106 14.1 OVERVIEW 107 14.2 IN VITRO APPLICATION 109 14.2.1 IN VIVO APPLICATION 111 14.2.2 BIOPRODUCTION 112 14.2.3 OTHERS 112 14.2.4 SYNTHETIC BIOLOGY 113 14.2.5 AGRICULTURE 113 14.2.6 OTHERS 113 15 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER 114 15.1 OVERVIEW 115 15.2 BIOPHARMA 118 15.3 CROS 118 15.4 CMOS/CDMOS 119 15.5 ACADEMIA 120 15.6 HOSPITALS 121 15.7 CLINICAL LABS 122 15.8 OTHERS 123 16 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL 124 16.1 OVERVIEW 125 16.2 DIRECT TENDER 128 16.3 RETAIL SALES 129 16.4 OTHERS 130 17 MIDDLE EAST & AFRICA TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION 131 17.1 MIDDLE EAST AND AFRICA 132 17.1.1 SOUTH AFRICA 137 17.1.2 SAUDI ARABIA 137 17.1.3 U.A.E. 137 17.1.4 EGYPT 137 17.1.5 ISRAEL 137 17.1.6 REST OF MIDDLE EAST AND AFRICA 137 18 MIDDLE EAST & AFRICA TRANSFECTION REAGENTS AND EQUIPMENT MARKET, COMPANY LANDSCAPE 138 18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 138 19 SWOT ANALYSIS 139 20 COMPANY PROFILE 140 20.1 THERMO FISHER SCIENTIFIC INC. 140 20.1.1 COMPANY SNAPSHOT 140 20.1.2 REVENUE ANALYSIS 140 20.1.3 COMPANY SHARE ANALYSIS 141 20.1.4 PRODUCT PORTFOLIO 141 20.1.5 RECENT DEVELOPMENT 142 20.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 143 20.2.1 COMPANY SNAPSHOT 143 20.2.2 REVENUE ANALYSIS 143 20.2.3 COMPANY SHARE ANALYSIS 144 20.2.4 PRODUCT PORTFOLIO 144 20.2.5 RECENT DEVELOPMENT 145 20.3 PROMEGA CORPORATION 146 20.3.1 COMPANY SNAPSHOT 146 20.3.2 COMPANY SHARE ANALYSIS 146 20.3.3 PRODUCT PORTFOLIO 147 20.3.4 RECENT DEVELOPMENT 147 20.4 TAKARA BIO INC. 148 20.4.1 COMPANY SNAPSHOT 148 20.4.2 REVENUE ANALYSIS 148 20.4.3 COMPANY SHARE ANALYSIS 149 20.4.4 PRODUCT PORTFOLIO 149 20.4.5 RECENT DEVELOPMENT 149 20.5 BIO-RAD LABORATORIES, INC. 150 20.5.1 COMPANY SNAPSHOT 150 20.5.2 REVENUE ANANLYSIS 150 20.5.3 COMPANY SHARE ANALYSIS 151 20.5.4 PRODUCT PORTFOLIO 151 20.5.5 RECENT DEVELOPMENT 152 20.6 ALTOGEN BIOSYSTEMS 153 20.6.1 COMPANY SNAPSHOT 153 20.6.2 PRODUCT PORTFOLIO 153 20.6.3 RECENT DEVELOPMENT 154 20.7 APPLIED BIOLOGICAL MATERIALS INC. (ABM) 155 20.7.1 COMPANY SNAPSHOT 155 20.7.2 PRODUCT PORTFOLIO 155 20.7.3 RECENT DEVELOPMENT 155 20.8 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC) 156 20.8.1 COMPANY SNAPSHOT 156 20.8.2 REVENUE ANALYSIS 156 20.8.3 PRODUCT PORTFOLIO 157 20.8.4 RECENT DEVELOPMENT 157 20.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER) 158 20.9.1 COMPANY SNAPSHOT 158 20.9.2 PRODUCT PORTFOLIO 158 20.9.3 RECENT DEVELOPMENT 158 20.10 CYTIVA 159 20.10.1 COMPANY SNAPSHOT 159 20.10.2 PRODUCT PORTFOLIO 159 20.10.3 RECENT DEVELOPMENT 159 20.11 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION) 160 20.11.1 COMPANY SNAPSHOT 160 20.11.2 REVENUE ANANLYSIS 160 20.11.3 PRODUCT PORTFOLIO 161 20.11.4 RECENT DEVELOPMENT 161 20.12 GENLANTIS INC. 162 20.12.1 COMPANY SNAPSHOT 162 20.12.2 PRODUCT PORTFOLIO 162 20.12.3 RECENT DEVELOPMENT 162 20.13 GENO TECHNOLOGY INC., USA 163 20.13.1 COMPANY SNAPSHOT 163 20.13.2 PRODUCT PORTFOLIO 163 20.13.3 RECENT DEVELOPMENT 163 20.14 GINKGO BIOWORKS 164 20.14.1 COMPANY SNAPSHOT 164 20.14.2 PRODUCT PORTFOLIO 164 20.14.3 RECENT DEVELOPMENTS 164 20.15 LONZA 165 20.15.1 COMPANY SNAPSHOT 165 20.15.2 REVENUE ANANLYSIS 165 20.15.3 PRODUCT PORTFOLIO 166 20.15.4 RECENT DEVELOPMENT 166 20.16 MAXCYTE, INC. 167 20.16.1 COMPANY SNAPSHOT 167 20.16.2 REVENUE ANALYSIS 167 20.16.3 PRODUCT PORTFOLIO 168 20.16.4 RECENT DEVELOPMENT 168 20.17 MERCK KGAA 169 20.17.1 COMPANY SNAPSHOT 169 20.17.2 REVENUE ANALYSIS 169 20.17.3 PRODUCT PORTFOLIO 170 20.17.4 RECENT DEVELOPMENT 170 20.18 MIRUS BIO LLC. 171 20.18.1 COMPANY SNAPSHOT 171 20.18.2 PRODUCT PORTFOLIO 171 20.18.3 RECENT DEVELOPMENT 171 20.19 ORIGENE TECHNOLOGIES, INC. 173 20.19.1 COMPANY SNAPSHOT 173 20.19.2 PRODUCT PORTFOLIO 173 20.19.3 RECENT DEVELOPMENT 173 20.20 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.) 174 20.20.1 COMPANY SNAPSHOT 174 20.20.2 REVENUE ANALYSIS 174 20.20.3 PRODUCT PORTFOLIO 175 20.20.4 RECENT DEVELOPMENT 175 20.21 POLYPLUS TRANSFECTION 176 20.21.1 COMPANY SNAPSHOT 176 20.21.2 PRODUCT PORTFOLIO 176 20.21.3 RECENT DEVELOPMENT 176 20.22 R&D SYSTEMS, INC. 178 20.22.1 COMPANY SNAPSHOT 178 20.22.2 PRODUCT PORTFOLIO 178 20.22.3 RECENT DEVELOPMENT 178 20.23 SBS GENETECH 179 20.23.1 COMPANY SNAPSHOT 179 20.23.2 PRODUCT PORTFOLIO 179 20.23.3 RECENT DEVELOPMENT 179 20.24 SIGNAGEN LABORATORIES 180 20.24.1 COMPANY SNAPSHOT 180 20.24.2 PRODUCT PORTFOLIO 180 20.24.3 RECENT DEVELOPMENT 180 21 QUESTIONNAIRE 182 22 RELATED REPORTS 187